De Palo Micaela, Guida Pietro, Mastro Florinda, Nanna Daniela, Quagliara Teresa A P, Rociola Ruggiero, Lionetti Giosuè, Paparella Domenico
Department of Emergency and Organ Transplant, Division of Cardiac Surgery, University of Bari Aldo Moro, Bari, Italy.
Perfusion. 2017 Apr;32(3):245-252. doi: 10.1177/0267659116679249. Epub 2016 Nov 14.
Myocardial damage is an independent predictor of adverse outcome following cardiac surgery and myocardial protection is one of the key factors to achieve successful outcomes. Cardioplegia with Custodiol is currently the most used cardioplegia during minimally invasive cardiac surgery (MICS). Different randomized controlled trials compared blood and Custodiol cardioplegia in the context of traditional cardiac surgery. No data are available for MICS.
The aim of this study was to compare the efficacy of cold blood versus Custodiol cardioplegia during MICS.
We retrospectively evaluated 90 patients undergoing MICS through a right mini-thoracotomy in a three-year period. Myocardial protection was performed using cold blood (44 patients, CBC group) or Custodiol (46 patients, Custodiol group) cardioplegia, based on surgeon preference and complexity of surgery.
The primary outcomes were post-operative cardiac troponin I (cTnI) and creatine kinase MB (CKMB) serum release and the incidence of Low Cardiac Output Syndrome (LCOS). Aortic cross-clamp and cardiopulmonary bypass times were higher in the Custodiol group. No difference was observed in myocardial injury enzyme release (peak cTnI value was 18±46 ng/ml in CBC and 21±37 ng/ml in Custodiol; p=0.245). No differences were observed for mortality, LCOS, atrial or ventricular arrhythmias onset, transfusions, mechanical ventilation time duration, intensive care unit and total hospital stay.
Custodiol and cold blood cardioplegic solutions seem to assure similar myocardial protection in patients undergoing cardiac surgery through a right mini-thoracotomy approach.
心肌损伤是心脏手术后不良预后的独立预测因素,心肌保护是实现成功手术结果的关键因素之一。在微创心脏手术(MICS)中,含科停多醇(Custodiol)的心脏停搏液是目前最常用的心脏停搏液。不同的随机对照试验在传统心脏手术背景下比较了血液停搏液和含科停多醇心脏停搏液。尚无关于微创心脏手术的相关数据。
本研究的目的是比较微创心脏手术中冷血停搏液与含科停多醇心脏停搏液的疗效。
我们回顾性评估了在三年期间通过右胸小切口接受微创心脏手术的90例患者。根据外科医生的偏好和手术复杂性,使用冷血停搏液(44例患者,CBC组)或含科停多醇(46例患者,Custodiol组)心脏停搏液进行心肌保护。
主要结局指标为术后心肌肌钙蛋白I(cTnI)和肌酸激酶同工酶MB(CKMB)的血清释放量以及低心排血量综合征(LCOS)的发生率。Custodiol组的主动脉阻断和体外循环时间更长。心肌损伤酶释放方面未观察到差异(CBC组的cTnI峰值为18±46 ng/ml,Custodiol组为21±37 ng/ml;p = 0.245)。在死亡率、LCOS、房性或室性心律失常的发生、输血、机械通气时间、重症监护病房住院时间和总住院时间方面均未观察到差异。
对于通过右胸小切口进行心脏手术的患者,含科停多醇心脏停搏液和冷血停搏液似乎能提供相似的心肌保护。